124 related articles for article (PubMed ID: 23775776)
21. Improved Stability of a Model IgG3 by DoE-Based Evaluation of Buffer Formulations.
Chavez BK; Agarabi CD; Read EK; Boyne MT; Khan MA; Brorson KA
Biomed Res Int; 2016; 2016():2074149. PubMed ID: 27042659
[TBL] [Abstract][Full Text] [Related]
22. Examination of thermal unfolding and aggregation profiles of a series of developable therapeutic monoclonal antibodies.
Brader ML; Estey T; Bai S; Alston RW; Lucas KK; Lantz S; Landsman P; Maloney KM
Mol Pharm; 2015 Apr; 12(4):1005-17. PubMed ID: 25687223
[TBL] [Abstract][Full Text] [Related]
23. Quality by design: impact of formulation variables and their interactions on quality attributes of a lyophilized monoclonal antibody.
Awotwe-Otoo D; Agarabi C; Wu GK; Casey E; Read E; Lute S; Brorson KA; Khan MA; Shah RB
Int J Pharm; 2012 Nov; 438(1-2):167-75. PubMed ID: 22944306
[TBL] [Abstract][Full Text] [Related]
24. Effects of solution conditions, processing parameters, and container materials on aggregation of a monoclonal antibody during freeze-thawing.
Kueltzo LA; Wang W; Randolph TW; Carpenter JF
J Pharm Sci; 2008 May; 97(5):1801-12. PubMed ID: 17823949
[TBL] [Abstract][Full Text] [Related]
25. The freezing step in lyophilization: physico-chemical fundamentals, freezing methods and consequences on process performance and quality attributes of biopharmaceuticals.
Kasper JC; Friess W
Eur J Pharm Biopharm; 2011 Jun; 78(2):248-63. PubMed ID: 21426937
[TBL] [Abstract][Full Text] [Related]
26. Role of cosolutes in the aggregation kinetics of monoclonal antibodies.
Nicoud L; Sozo M; Arosio P; Yates A; Norrant E; Morbidelli M
J Phys Chem B; 2014 Oct; 118(41):11921-30. PubMed ID: 25243487
[TBL] [Abstract][Full Text] [Related]
27. Structural properties of monoclonal antibody aggregates induced by freeze-thawing and thermal stress.
Hawe A; Kasper JC; Friess W; Jiskoot W
Eur J Pharm Sci; 2009 Sep; 38(2):79-87. PubMed ID: 19540340
[TBL] [Abstract][Full Text] [Related]
28. Stability of monoclonal antibodies at high-concentration: head-to-head comparison of the IgG1 and IgG4 subclass.
Neergaard MS; Nielsen AD; Parshad H; Van De Weert M
J Pharm Sci; 2014 Jan; 103(1):115-27. PubMed ID: 24282022
[TBL] [Abstract][Full Text] [Related]
29. Investigations into the fouling mechanism of parvovirus filters during filtration of freeze-thawed mAb drug substance solutions.
Barnard JG; Kahn D; Cetlin D; Randolph TW; Carpenter JF
J Pharm Sci; 2014 Mar; 103(3):890-9. PubMed ID: 24549732
[TBL] [Abstract][Full Text] [Related]
30. Freeze-drying of nanosuspensions, 1: freezing rate versus formulation design as critical factors to preserve the original particle size distribution.
Beirowski J; Inghelbrecht S; Arien A; Gieseler H
J Pharm Sci; 2011 May; 100(5):1958-68. PubMed ID: 21374626
[TBL] [Abstract][Full Text] [Related]
31. Freeze-thaw characterization process to minimize aggregation and enable drug product manufacturing of protein based therapeutics.
Jain K; Salamat-Miller N; Taylor K
Sci Rep; 2021 May; 11(1):11332. PubMed ID: 34059716
[TBL] [Abstract][Full Text] [Related]
32. The effect of temperature at which slow cooling is terminated and of thawing rate on the survival of one-cell mouse embryos frozen in dimethyl sulfoxide or 1,2-propanediol solutions.
Van den Abbeel E; Van der Elst J; Van Steirteghem AC
Cryobiology; 1994 Oct; 31(5):423-33. PubMed ID: 7988151
[TBL] [Abstract][Full Text] [Related]
33. First-order nucleation and subsequent growth promote liquid-liquid phase separation of a model IgG1 mAb.
Tian Z; Xu L; Zhang N; Qian F
Int J Pharm; 2020 Oct; 588():119681. PubMed ID: 32721563
[TBL] [Abstract][Full Text] [Related]
34. Rational design of viscosity reducing mutants of a monoclonal antibody: hydrophobic versus electrostatic inter-molecular interactions.
Nichols P; Li L; Kumar S; Buck PM; Singh SK; Goswami S; Balthazor B; Conley TR; Sek D; Allen MJ
MAbs; 2015; 7(1):212-30. PubMed ID: 25559441
[TBL] [Abstract][Full Text] [Related]
35. Frozen state storage instability of a monoclonal antibody: aggregation as a consequence of trehalose crystallization and protein unfolding.
Singh SK; Kolhe P; Mehta AP; Chico SC; Lary AL; Huang M
Pharm Res; 2011 Apr; 28(4):873-85. PubMed ID: 21213025
[TBL] [Abstract][Full Text] [Related]
36. Temperature Based Process Characterization of Pharmaceutical Freeze-Thaw Operations.
Weber D; Hubbuch J
Front Bioeng Biotechnol; 2021; 9():617770. PubMed ID: 33898399
[TBL] [Abstract][Full Text] [Related]
37. The effect of mAb and excipient cryoconcentration on long-term frozen storage stability - part 2: Aggregate formation and oxidation.
Bluemel O; Buecheler JW; Hauptmann A; Hoelzl G; Bechtold-Peters K; Friess W
Int J Pharm X; 2022 Dec; 4():100109. PubMed ID: 35024604
[TBL] [Abstract][Full Text] [Related]
38. Gelation of a monoclonal antibody at the silicone oil-water interface and subsequent rupture of the interfacial gel results in aggregation and particle formation.
Mehta SB; Lewus R; Bee JS; Randolph TW; Carpenter JF
J Pharm Sci; 2015 Apr; 104(4):1282-90. PubMed ID: 25639229
[TBL] [Abstract][Full Text] [Related]
39. Study of aggregation in therapeutic monoclonal antibodies subjected to stress and long-term stability tests by analyzing size exclusion liquid chromatographic profiles.
Hernández-Jiménez J; Martínez-Ortega A; Salmerón-García A; Cabeza J; Prados JC; Ortíz R; Navas N
Int J Biol Macromol; 2018 Oct; 118(Pt A):511-524. PubMed ID: 29944945
[TBL] [Abstract][Full Text] [Related]
40. Investigation of freezing- and thawing-induced biological, chemical, and physical changes to enoxaparin solution.
Patel RP; Narkowicz C; Jacobson GA
J Pharm Sci; 2009 Mar; 98(3):1118-28. PubMed ID: 18661541
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
